Neurocrine Biosciences (NASDAQ:NBIX) is a biotech firm engaged in discovering, developing, and commercializing innovative drugs for the treatment of neurologic, psychiatric, and endocrine-related diseases and disorders. The company focuses on advancing treatments for conditions with high unmet medical needs, such as Parkinson’s disease, tardive dyskinesia, and endometriosis. Neurocrine Biosciences is committed to improving patient outcomes through science-driven solutions. With a robust pipeline of potential therapies in various stages of clinical development, the company aims to deliver breakthrough medications that can significantly improve the quality of life for patients struggling with chronic and debilitating diseases.